GTP-004

Drug Profile

GTP-004

Alternative Names: GTP 004

Latest Information Update: 21 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Georgetown Translational Pharmaceuticals
  • Class
  • Mechanism of Action Acetylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Myasthenia gravis

Most Recent Events

  • 18 Aug 2017 GTP has patents pending for GTP-004 in USA
  • 08 Aug 2017 GTP has filed an orphan drug application in the US for the treatment of Myasthenia gravis
  • 08 Aug 2017 Georgetown Translational Pharmaceuticals plans to file an IND application with the USFDA in USA for Myasthenia gravis in the fourth quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top